Primary Myelofibrosis (PMF)
19
6
7
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
5.3%
1 terminated out of 19 trials
88.9%
+2.3% vs benchmark
16%
3 trials in Phase 3/4
75%
6 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (19)
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Extended Access of Momelotinib in Adults With Myelofibrosis
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis
Managed Access Programs for INC424, Ruxolitinib
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)